ANNOVIS BIO ANNOUNCES PATIENT ENROLLMENT UPDATE FOR PHASE 3 STUDY OF BUNTANETAP FOR THE TREATMENT OF PARKINSON'S DISEASE

Strong enrollment in Phase 3 trial demonstrates continued executionInterim analysis expected in 2Q 2023
BERWYN, Pa., Jan. 25, 2023  /PRNewswire/ -- Annovis Bio, Inc. (NYSE: ANVS) (

Related Keywords

Berwyn ,Pennsylvania ,United States ,Marial Maccecchini ,Kevin Gardner ,Nic Johnson ,Annovis Bio ,Chris Calabrese ,Exchange Commission ,Company Phase ,Lifesci Advisors ,Movement Disorder Society ,Annovis Bio Inc ,Russo Partners ,Disorder Society Sponsored Revision ,Unified Parkinson ,Disease Rating Scale ,Participant Global Impression ,Wechsler Adult Intelligence Scale ,Mini Mental State Examination ,Buntanetap Proves Promising ,Both Alzheimer ,Private Securities Litigation Reform Act ,Annual Report ,Sci Advisors ,